AB0558 ANIFROLUMAB IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS: A REAL-LIFE, MULTICENTER STUDY
AB0558 ANIFROLUMAB IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS: A REAL-LIFE, MULTICENTER STUDY
About this item
Full title
Author / Creator
Trentin, F. , Tani, C. , Cauli, A. , Ceccarelli, F. , Ciccia, F. , Conti, F. , Coladonato, L. , Dagna, L. , De Marchi, G. , Emmi, G. , Fasano, S. , Gatto, M. , Moroni, L. , Riccio, F. , Piga, M. , Zen, M. and Mosca, M.
Publisher
Kidlington: Elsevier B.V
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier B.V
Subjects
More information
Scope and Contents
Contents
Anifrolumab (ANI) is a monoclonal antibody to the type I interferon receptor recently approved by EMA as an add-on therapy for the treatment of moderate to severe SLE. As of this writing, real world data on its use are still lacking.
To depict the clinical phenotype of refractory SLE patients treated with ANI. To evaluate short-term effectivenes...
Alternative Titles
Full title
AB0558 ANIFROLUMAB IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS: A REAL-LIFE, MULTICENTER STUDY
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2825233673
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2825233673
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2023-eular.3552
